More Studies Needed to Optimize the Use of Osteoporosis Drugs

Save

The Annals of Internal Medicine reports a metanalysis done to examine the optimal length of long-term osteoporosis drug treatment (ODT) and whether harms are associated with long-term ODT and while the ODT benefits are clear, the risk of rare harms and need for drug holidays is less certain.&nbsp

Skyrizi (risankizumab) FDA Approved for Psoriasis

Save

AbbVie has announced that the US FDA has granted the approval of Skyrizi (risankizumab-rzaa) for the treatment of moderate to severe plaque psoriasis. 

Ustekinumab Effective in Behcet's Disease

Save

A small prospective study has shown that ustekinumab is safe and effective in Behçet's disease (BD) with recurrent oral ulcers (OU).

NIH Workshop on Unmet Needs in Osteoporosis

Save

In October 2018, the National Institutes of Health (NIH) convened a workshop to address the "Appropriate Use of Drug Therapies for Osteoporotic Fracture Prevention"

Improved Survival in Lupus

Save

A longitudinal study of systemic lupus erythematosus (SLE) from the Toronto Lupus Clinic has shown that mortality has decreased over time.

Statins in RA Patients Without CVD: Nonsignificant Results

Save

Patients with RA, but without CV disease, who were treated with atorvastatin appeared to experience cardiovascular (CV) benefits similar to what has been observed in other populations, with a risk reduction of approximately one-third, according to a large, but prematurely terminated, trial in the

Sleep Myths Debunked

Save

A panel of 10 sleep experts studied 20 common sleep myths and found little or no evidence in support of these beliefs.

Sleep issues are highly prevalent among US adults, but few admit to it or do anything to manage it.